REHOVOT, Israel, Oct. 22, 2019 /PRNewswire/
-- CollPlant (NASDAQ: CLGN), a regenerative medicine
company, today announced the Company's Chief Executive Officer
Yehiel Tal was recently appointed as
a member of the Industry Relations Committee of ISBF (International
Society for Biofabrication). The committee convened during the
International Conference on Biofabrication on October 20-22, 2019 in Columbus, Ohio.
Mr. Tal was appointed to the Industry Relations Committee in
recognition of his deep involvement in the 3D bioprinting industry.
The committee is tasked with advancing the Biofabrication industry
by: serving as a mediator of academia-industry and
industry-industry to promote and stimulate collaboration;
developing mechanisms to facilitate translation of laboratory
discoveries into manufactured products; and representing the
industry in all Biofabrication aspects including roadmap,
technologies, cell biology, large scale manufacturing, regulation,
and commercialization.
At the International Conference on Biofabrication, CollPlant
also presented a poster regarding CollPlant's rhCollagen technology
titled, "Recombinant Human Type I Collagen a Flexible BioInk
Platform for 3D Bioprinting."
"I am honored to be appointed to the International Society for
Biofabrication's Industry Relations Committee, and to work with
others who are shaping and advancing this promising field of
regenerative medicine. In order to advance the development of
ground breaking research and development into products, our
committee will aim to create collaborative partnerships amongst
stakeholders including industry, academia, and regulatory agencies.
I am proud to be part of this process," stated Mr. Tal.
About the International Society for Biofabrication
From basic science to medical applications, the biofabrication
community convened at the International Conference on
Biofabrication (Biofabrication 2019). The field of biofabrication
is dedicated to researching and integrating technologies such as
bio-printing, bio-plotting, and bio-assembly into applications such
as engineered tissue systems and regenerative medicine. The
International Society for Biofabrication's (ISBF) core purpose is
to foster scientific and technological innovation and excellence
for the benefit of humanity. ISBF promotes the interaction between
and convergence in the different disciplines of the field of
Biofabrication, as well as between basic research and applied
practice. Further, the Society aims to promote the cooperation with
other scientific organizations and communities.
About CollPlant
CollPlant is a regenerative medicine company focused on 3D
bioprinting of tissues and organs, and medical aesthetics.
Our products are based on our rhCollagen (recombinant human
collagen) that is produced with CollPlant's proprietary plant based
genetic engineering technology.
Our products address indications for the diverse fields of organ
and tissue repair, and are ushering in a new era in regenerative
medicine. Our flagship rhCollagen BioInk product line is ideal for
3D bioprinting of tissues and organs. In October 2018, we entered into a licensing
agreement with United Therapeutics, whereby United Therapeutics is
using CollPlant's BioInks in the manufacture of 3D bioprinted lungs
for transplant in humans.
For more information about CollPlant, visit
http://www.collplant.com
Safe Harbor Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that CollPlant intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause CollPlant's actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company's history of significant
losses, its ability to continue as a going concern, and its need to
raise additional capital and its inability to obtain additional
capital on acceptable terms, or at all; the Company's expectations
regarding the timing and cost of commencing clinical trials with
respect to tissues and organs which are based on its rhCollagen
based BioInk, dermal fillers for aesthetics, VergenixSTR, and
VergenixFG; the Company's ability to obtain favorable pre-clinical
and clinical trial results; regulatory action with respect to
rhCollagen based BioInk, dermal fillers for aesthetics,
VergenixSTR, and VergenixFG including but not limited to acceptance
of an application for marketing authorization, review and approval
of such application, and, if approved, the scope of the approved
indication and labeling; commercial success and market acceptance
of the Company's rhCollagen based BioInk, dermal fillers for
aesthetics, VergenixSTR, and VergenixFG; the Company's ability to
establish sales and marketing capabilities or enter into agreements
with third parties and its reliance on third party distributors and
resellers; the Company's ability to establish and maintain
strategic partnerships and other corporate collaborations; the
Company's reliance on third parties to conduct some or all aspects
of its product manufacturing; the scope of protection the Company
is able to establish and maintain for intellectual property rights
and the Company's ability to operate its business without
infringing the intellectual property rights of others; the overall
global economic environment; the impact of competition and new
technologies; general market, political, and economic conditions in
the countries in which the Company operates; projected capital
expenditures and liquidity; changes in the Company's strategy; and
litigation and regulatory proceedings. More detailed information
about the risks and uncertainties affecting CollPlant is contained
under the heading "Risk Factors" included in CollPlant's most
recent annual report on Form 20-F filed with the SEC, and in other
filings that CollPlant has made and may make with the SEC in the
future. The forward-looking statements contained in this press
release are made as of the date of this press release and reflect
CollPlant's current views with respect to future events, and
CollPlant does not undertake and specifically disclaims any
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact at CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@collplant.com
View original
content:http://www.prnewswire.com/news-releases/collplant-ceo-yehiel-tal-appointed-to-serve-on-international-society-for-biofabrications-industry-relations-committee-300942753.html
SOURCE CollPlant